A list of puns related to "Immunogen"
ImmunoGen stock (NASDAQ: IMGN) soared over 48% in Tuesday premarket trading, with investors reacting kindly to a successful clinical trial, whereby the safety and efficacy of mirvetuximab soravtansine were tested in a pivotal study. The drug proved effective with patients suffering from ovarian cancer – meeting the goals of the study’s primary endpoint.
The positive results followed the SORAYA trial, a single-arm study of mirvetuximab in patients with platinum-resistant ovarian cancer who have been previously treated with cancer drug Avastin. The study showed a confirmed objective response rate of 32.4% – demonstrating impressive activity in patients with ovarian cancer.
The company is hoping to file with the FDA for approval in Q122, followed by the gathering of further top-line data later in the year to solidify data for full approval.
Mark Enyedy, ImmunoGen President and CEO, expresses his excitement:
“This is an exciting moment, both for the field of ovarian cancer and for ImmunoGen, and the outcomes from SORAYA further validate our longstanding history of innovation in ADCs,”
Adding…
“We are moving forward expeditiously to complete the BLA for mirvetuximab, with the goal of submitting the application to FDA for accelerated approval in the first quarter of 2022. In parallel, commercial preparations are well underway to support the potential launch of mirvetuximab next year.”
If you’re looking at ImmunoGen for an investment opportunity, it might be worth waiting for a retracement on today’s premarket rally, or perhaps on further news regarding any submissions for approval. IMGN stock started to trail of after a strong start to the year, showing an annual loss of 26%. Covering prominent ground in a critical space, ImmunoGen might be worth keeping an eye on.
https://bisouv.com/uncategorized/1626656/cancer-targeted-therapy-market-future-prospects-2026-boehringer-ingelheim-genetech-immunogen-bind-therapeutics-inovio-pharmaceuticals/
Deals with various countries along with vaccine orders are on the way....Sinovac Booster approval in China is looming large....Massive Vaccine orders will follow......Right dealing with Covid is the most important thing in the world......INOVIO is poised for greatness with INO 4800 Covid 19 Vaccine and VGX 3100 for HPV/Cervical Cancer in Phase 3......Plus 10 other vaccines and medicines in Phase 2.....$400,000,000 in cash......INOVIO should have 3 commercialized vaccines/medicines in less than a year.....INO 4800 sales in less than 30 to 60 days.....MERS and Lassa fever Vaccine stockpiles for CEPI.....CEPI is funding INOVIO $56,000,000 towards this program.....CEPI stated they want a stockpile of these vaccines.....Controlling these infectious diseases is vital to the planet......VGX 3100 is headed for approval.....$500,000,000 market for this treatment.....INOVIO's working with QIAGEN a 12 $Billion dollar public diagnostics company......QIAGEN's biomarkers will give INOVIO 85% assurity which women are eligible for this treatment.....Precise science and medicine!!!!!......If you look at INOVIO's website you can see the quality of the people involved with INOVIO......30 Fold gains in this stock in 18 months or less!!!!!!.....Did I miss anything?
Please note that this site uses cookies to personalise content and adverts, to provide social media features, and to analyse web traffic. Click here for more information.